Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure

Matthew Bidwell Goetz, Monique Ferguson, Xueliang Han, Greg McMillan, Marty St Clair, Keith A. Pappa, Daniel R. McClernon, William A. O'Brien

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE: We compared the rate of emergence of thymidine analogue mutations (TAMs) and major protease inhibitor mutations in adherent patients who remained on stable treatment with a thymidine analogue and/or protease inhibitor after the onset of virologic failure. DESIGN: Follow-up genotypic resistance testing was done using archived plasma obtained from patients having 0 or 1 TAM and/or 0 or 1 major protease inhibitor resistance mutation at the onset of virologic failure. RESULTS: The median duration of observed failure was 691 days. There were 41 thymidine analogue regimens and 34 protease inhibitor regimens; concomitant ritonavir was used 4 times. New major protease inhibitor mutations emerged more rapidly than did new TAMs (P = 0.0019); new TAMs emerged more rapidly in thymidine analogue regimens that did not include lamivudine (P = 0.0073). The emergence of TAMs and major protease inhibitor mutations did not differ if lamivudine was not part of the thymidine analogue regimen. The evolution of CD4 cell counts and plasma viral loads (pVLs) during virologic failure was similar regardless of whether or not a new TAM or major protease inhibitor mutations emerged or, for thymidine analogue-containing regimens, whether lamivudine was or was not used. CONCLUSIONS: Major protease inhibitor mutations arose more frequently and rapidly than did TAMs in patients with sustained virologic failure who received lamivudine.

Original languageEnglish (US)
Pages (from-to)541-549
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume43
Issue number5
DOIs
StatePublished - Dec 2006

Fingerprint

Thymidine
HIV
Protease Inhibitors
Mutation
Lamivudine
Therapeutics
Ritonavir
CD4 Lymphocyte Count
Viral Load

Keywords

  • HIV resistance
  • Protease inhibitors
  • Resistance mutations
  • Reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. / Goetz, Matthew Bidwell; Ferguson, Monique; Han, Xueliang; McMillan, Greg; Clair, Marty St; Pappa, Keith A.; McClernon, Daniel R.; O'Brien, William A.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 5, 12.2006, p. 541-549.

Research output: Contribution to journalArticle

Goetz, Matthew Bidwell ; Ferguson, Monique ; Han, Xueliang ; McMillan, Greg ; Clair, Marty St ; Pappa, Keith A. ; McClernon, Daniel R. ; O'Brien, William A. / Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. In: Journal of Acquired Immune Deficiency Syndromes. 2006 ; Vol. 43, No. 5. pp. 541-549.
@article{8ba5584c46024d31bdcfdc11bfe717b6,
title = "Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure",
abstract = "OBJECTIVE: We compared the rate of emergence of thymidine analogue mutations (TAMs) and major protease inhibitor mutations in adherent patients who remained on stable treatment with a thymidine analogue and/or protease inhibitor after the onset of virologic failure. DESIGN: Follow-up genotypic resistance testing was done using archived plasma obtained from patients having 0 or 1 TAM and/or 0 or 1 major protease inhibitor resistance mutation at the onset of virologic failure. RESULTS: The median duration of observed failure was 691 days. There were 41 thymidine analogue regimens and 34 protease inhibitor regimens; concomitant ritonavir was used 4 times. New major protease inhibitor mutations emerged more rapidly than did new TAMs (P = 0.0019); new TAMs emerged more rapidly in thymidine analogue regimens that did not include lamivudine (P = 0.0073). The emergence of TAMs and major protease inhibitor mutations did not differ if lamivudine was not part of the thymidine analogue regimen. The evolution of CD4 cell counts and plasma viral loads (pVLs) during virologic failure was similar regardless of whether or not a new TAM or major protease inhibitor mutations emerged or, for thymidine analogue-containing regimens, whether lamivudine was or was not used. CONCLUSIONS: Major protease inhibitor mutations arose more frequently and rapidly than did TAMs in patients with sustained virologic failure who received lamivudine.",
keywords = "HIV resistance, Protease inhibitors, Resistance mutations, Reverse transcriptase inhibitors",
author = "Goetz, {Matthew Bidwell} and Monique Ferguson and Xueliang Han and Greg McMillan and Clair, {Marty St} and Pappa, {Keith A.} and McClernon, {Daniel R.} and O'Brien, {William A.}",
year = "2006",
month = "12",
doi = "10.1097/01.qai.0000245882.28391.0c",
language = "English (US)",
volume = "43",
pages = "541--549",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure

AU - Goetz, Matthew Bidwell

AU - Ferguson, Monique

AU - Han, Xueliang

AU - McMillan, Greg

AU - Clair, Marty St

AU - Pappa, Keith A.

AU - McClernon, Daniel R.

AU - O'Brien, William A.

PY - 2006/12

Y1 - 2006/12

N2 - OBJECTIVE: We compared the rate of emergence of thymidine analogue mutations (TAMs) and major protease inhibitor mutations in adherent patients who remained on stable treatment with a thymidine analogue and/or protease inhibitor after the onset of virologic failure. DESIGN: Follow-up genotypic resistance testing was done using archived plasma obtained from patients having 0 or 1 TAM and/or 0 or 1 major protease inhibitor resistance mutation at the onset of virologic failure. RESULTS: The median duration of observed failure was 691 days. There were 41 thymidine analogue regimens and 34 protease inhibitor regimens; concomitant ritonavir was used 4 times. New major protease inhibitor mutations emerged more rapidly than did new TAMs (P = 0.0019); new TAMs emerged more rapidly in thymidine analogue regimens that did not include lamivudine (P = 0.0073). The emergence of TAMs and major protease inhibitor mutations did not differ if lamivudine was not part of the thymidine analogue regimen. The evolution of CD4 cell counts and plasma viral loads (pVLs) during virologic failure was similar regardless of whether or not a new TAM or major protease inhibitor mutations emerged or, for thymidine analogue-containing regimens, whether lamivudine was or was not used. CONCLUSIONS: Major protease inhibitor mutations arose more frequently and rapidly than did TAMs in patients with sustained virologic failure who received lamivudine.

AB - OBJECTIVE: We compared the rate of emergence of thymidine analogue mutations (TAMs) and major protease inhibitor mutations in adherent patients who remained on stable treatment with a thymidine analogue and/or protease inhibitor after the onset of virologic failure. DESIGN: Follow-up genotypic resistance testing was done using archived plasma obtained from patients having 0 or 1 TAM and/or 0 or 1 major protease inhibitor resistance mutation at the onset of virologic failure. RESULTS: The median duration of observed failure was 691 days. There were 41 thymidine analogue regimens and 34 protease inhibitor regimens; concomitant ritonavir was used 4 times. New major protease inhibitor mutations emerged more rapidly than did new TAMs (P = 0.0019); new TAMs emerged more rapidly in thymidine analogue regimens that did not include lamivudine (P = 0.0073). The emergence of TAMs and major protease inhibitor mutations did not differ if lamivudine was not part of the thymidine analogue regimen. The evolution of CD4 cell counts and plasma viral loads (pVLs) during virologic failure was similar regardless of whether or not a new TAM or major protease inhibitor mutations emerged or, for thymidine analogue-containing regimens, whether lamivudine was or was not used. CONCLUSIONS: Major protease inhibitor mutations arose more frequently and rapidly than did TAMs in patients with sustained virologic failure who received lamivudine.

KW - HIV resistance

KW - Protease inhibitors

KW - Resistance mutations

KW - Reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33845371783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845371783&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000245882.28391.0c

DO - 10.1097/01.qai.0000245882.28391.0c

M3 - Article

C2 - 17075391

AN - SCOPUS:33845371783

VL - 43

SP - 541

EP - 549

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -